Research progress on pharmacological effects of isoalantolactone.

isoalantolactone mechanisms pharmacokinetic pharmacological effects toxicity

Journal

The Journal of pharmacy and pharmacology
ISSN: 2042-7158
Titre abrégé: J Pharm Pharmacol
Pays: England
ID NLM: 0376363

Informations de publication

Date de publication:
17 Apr 2023
Historique:
received: 22 08 2022
accepted: 19 12 2022
medline: 18 4 2023
pubmed: 21 3 2023
entrez: 20 3 2023
Statut: ppublish

Résumé

To review the pharmacokinetics, pharmacological action and mechanism of isoalantolactone (IAL). Explore the therapeutic potential of isoalantolactone.Keywords including isoalantolactone, pharmacological effects, pharmacokinetic and toxicity were used for literature search in PubMed, Excerpta Medica Database (EMBASE) and Web of Science, to identify articles published from 1992 to 2022. IAL has a great many obiological activities such as anti-inflammatory, antioxidant, antitumour, neuroprotection, with no obvious toxicity. This review suggests that IAL exerts different pharmacological effects with different mechanisms of action at different doses, and may be a potential drug candidate to treat inflammatory diseases, neurodegenerative diseases and cancer, with medicinal value. IAL has various pharmacological activities and medicinal values. However, further research is needed to determine its specific intracellular action sites and targets, so as to fully understand its therapeutic mechanism and provide a reference for the treatment of related diseases.

Identifiants

pubmed: 36940405
pii: 7081216
doi: 10.1093/jpp/rgac103
doi:

Substances chimiques

isoalantolactone BYH07P620U
Anti-Inflammatory Agents 0
Sesquiterpenes 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

585-592

Subventions

Organisme : Hebei University
ID : 2020-8
Organisme : Natural Science Foundation of Hebei Province
ID : H2021201043

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Royal Pharmaceutical Society.

Auteurs

Lu Xu (L)

School of Basic Medical Science, Hebei University, Baoding, Hebei, P. R. China.

Yanan Sun (Y)

College of Traditional Chinese Medicine, Hebei University, Baoding, Hebei, P. R. China.

Qihan Cai (Q)

School of Basic Medical Science, Hebei University, Baoding, Hebei, P. R. China.

Mengmeng Wang (M)

School of Basic Medical Science, Hebei University, Baoding, Hebei, P. R. China.

Xinliang Wang (X)

School of Basic Medical Science, Hebei University, Baoding, Hebei, P. R. China.

Siming Wang (S)

School of Basic Medical Science, Hebei University, Baoding, Hebei, P. R. China.

Zhiyu Ni (Z)

Affiliated Hospital of Hebei University, Baoding, Hebei, P. R. China.
Clinical Medical College, Hebei University, Baoding, Hebei, P. R. China.
Hebei Collaborative Innovation Center of Tumor Microecological Metabolism Regulation, Baoding, Hebei, P. R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH